Charles River Laboratories International CRL
NYSE CRL
$282.06 +8.65 (+3.16%)
As of: Sep 17, 2026 · 3:59 PM EDT

Charles River Laboratories International (CRL) Cash from Discontinued Operations (2009 - 2018)

Charles River Laboratories International (CRL) posted Cash from Discontinued Operations of -$4000.0 for Q3 2018, up 99.87% on a QoQ basis from -$3.1 million in Q2 2018, and up 99.19% year-over-year from -$2008.2 in Q3 2017.

Analysis

Charles River Laboratories International (CRL) Cash from Discontinued Operations (2009 - 2018) Analysis & Trends

Charles River Laboratories International has reported Cash from Discontinued Operations for 10 years, with the latest figure at -$4000.0 in Q3 2018.

  • On a quarterly basis, Cash from Discontinued Operations rose 99.19% year-over-year to -$4000.0 in Q3 2018; TTM through Jun 2019 was -$4000.0, a 99.91% increase from a year earlier, with the FY2018 full-year figure at -$3.7 million, down 106.47% from the prior year.
  • Cash from Discontinued Operations was -$4000.0 for Q3 2018 at Charles River Laboratories International, up from -$3.1 million in the prior quarter.
  • The five-year high for Cash from Discontinued Operations was $119000.0 in Q3 2014, with the low at -$3.1 million in Q2 2018.
  • Average Cash from Discontinued Operations over 5 years is -$555631.6, with a median of -$492000.0 recorded in 2017.
  • The largest YoY upside for Cash from Discontinued Operations was 120.27% in 2014 against a maximum downside of 22033.33% in 2014.
  • Over 5 years, Cash from Discontinued Operations stood at -$511000.0 in 2014, then fell by 19.57% to -$611000.0 in 2015, then fell by 1.8% to -$622000.0 in 2016, then jumped by 48.55% to -$320000.0 in 2017, then jumped by 98.75% to -$4000.0 in 2018.
  • The last three Cash from Discontinued Operations figures came in at -$4000.0 (Q3 2018), -$3.1 million (Q2 2018), and -$636000.0 (Q1 2018), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Iqvia Holdings 44.72 Bn 42.64 Bn 1.44 Bn -
2 Medpace Holdings 17.37 Bn 16.87 Bn 201.64 Mn -
3 Icon 13.65 Bn 12.72 Bn 479.29 Mn -
4 Charles River Laboratories International 13.13 Bn 12.94 Bn 452.07 Mn -
5 Fortrea Holdings 1.89 Bn 1.72 Bn 139.20 Mn -
6 Evotec SE 574.75 Mn 148.87 Mn - -
7 Ginkgo Bioworks Holdings 439.63 Mn 355.09 Mn 18.44 Mn -2.10 Mn
8 Champions Oncology 69.43 Mn 65.03 Mn 7.70 Mn -
9 MindWalk Holdings 51.76 Mn 46.29 Mn 1.61 Mn -2.90 Mn
10 VivoSim Labs 1.37 Mn 1.37 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 29, 2018 -4,000.00
Jun 30, 2018 -3.10 Mn
Mar 31, 2018 -636,000.00
Dec 30, 2017 -320,000.00
Sep 30, 2017 -492,000.00
Jul 1, 2017 -524,000.00
Apr 1, 2017 -473,000.00
Dec 31, 2016 -622,000.00
Sep 24, 2016 -652,000.00
Jun 25, 2016 -293,000.00
Mar 26, 2016 -489,000.00
Dec 26, 2015 -611,000.00
Sep 26, 2015 -338,000.00
Jun 27, 2015 -611,000.00
Mar 28, 2015 -316,000.00
Dec 27, 2014 -511,000.00
Sep 27, 2014 119,000.00
Jun 28, 2014 -25,000.00
Mar 29, 2014 -664,000.00
Dec 28, 2013 -373,000.00